BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
Sanofi India Ltd.’s revenue declined by 2.5% YoY and came in 2.5% lower than our estimate but 7.6% higher than consensus estimate. Net profit (post exceptional items) stood at Rs 2,384 million, translating into an earnings per share of Rs 103/share (adjusted EPS of Rs 68/share).
Gross margin expanded by 244 basis points QoQ and 233 bps YoY despite elevated costs. Other expenses as a % of sales were sharply lower on a QoQ basis, but were in line with the historical annualised % of sales.
During the quarter, Sanofi India completed the divestment of its Soframycin and Sofradex portfolio to Encube Ethicals Pvt Ltd. for Rs 1,250 million.
Annual sales of the divested portfolio stood at Rs 754 million (2.6% of total sales).
Inclusion of Lantus in the National List of Essential Medicines list is yet to be implemented.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR